DIG
PTCT icon

Dauntless Investment Group’s PTC Therapeutics PTCT Stock Holding History

Dauntless Investment Group’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$831K Buy
10,193
+1,831
+22% +$132K 0.65% 31
2026
Q1 		$570K Buy
8,362
+3,600
+76% +$255K 0.38% 26
2025
Q4 		$362K Buy
+4,762
New +$346K 0.29% 41

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Dauntless Investment Group's PTCT Position: Q2 2026 in Review

Dauntless Investment Group increased its PTC Therapeutics (PTCT) stake by 22% in Q2 2026, buying an estimated $132K and bringing the position to 10,193 shares worth $831K. The position accounts for 0.65% of the portfolio, ranked #31.

Dauntless Investment Group first reported a position in PTCT in Q4 2025 and has held it in 3 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Dauntless Investment Group held 10,193 shares of PTC Therapeutics worth $831K as of Q2 2026.
  • Dauntless Investment Group bought 1,831 PTC Therapeutics shares in Q2 2026, an estimated $132K.
  • PTC Therapeutics made up 0.65% of Dauntless Investment Group's portfolio in Q2 2026, its #31 holding.
  • Dauntless Investment Group first reported a position in PTC Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Dauntless Investment Group's 13F filing for Q2 2026, filed 13 Aug 2026.